OraSure To Present Proposal For HIV Test Actual-Use Study At Blood Panel
This article was originally published in The Tan Sheet
Executive Summary
A proposal for an actual-use study on the OraQuick Advance Rapid HIV oral fluid specimen test in support of OTC status will be presented by OraSure Technologies at an upcoming FDA advisory panel, according to FDA
You may also be interested in...
OraSure OTC HIV Test To Enter Phase II Trials By Summer
HIV test kit manufacturer OraSure Technologies should be required to conduct actual-use studies as part of Phase III trial commitments, according to an FDA advisory panel
OraSure OTC HIV Test To Enter Phase II Trials By Summer
HIV test kit manufacturer OraSure Technologies should be required to conduct actual-use studies as part of Phase III trial commitments, according to an FDA advisory panel
OraSure OTC HIV Test To Enter Phase II Trials By Summer
HIV test kit manufacturer OraSure Technologies should be required to conduct actual-use studies as part of Phase III trial commitments, according to an FDA advisory panel